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lipid barrier in the stratum corneum
(Akiyama, 2006).
As illustrated here, mutation analysis
of the ALDH3A2 gene is a highly sensi-
tive method to confirm a diagnosis of
SLS, which does not require a skin biopsy
and can complement or replace FALDH
enzymatic assays or analysis in SLS.
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TO THE EDITOR
The c-RET proto-oncogene encodes a
receptor-tyrosine kinase and glial cell
line-derived neurotrophic factor ligands,
including glial cell line-derived neuro-
trophic factor, neurturin, artemin, and
persephin, have been reported to be
ligands of RET (Takahashi, 2001). RFP/
RET is a hybrid oncogene between c-
RET and RFP that was isolated by
NIH3T3 transfection assays (Takahashi
et al., 1985). Previously, we established
a metallothionein-I/RFP-RET (RET)-trans-
genic mouse line (242) that sponta-
neously develops systemic skin
melanosis without macroscopic tumors
(Iwamoto et al., 1991; Kato et al., 1999).
Generally, most hair follicles in adult
wild-type mice are in telogen (Kato
et al., 2001). It is basically impossible
to induce continuous anagen hair folli-
cles in adult wild-type mice, although
temporal anagen hair follicles are in-
ducible by shaving hairs (Kato et al.,
2001). Interestingly, adult RET-trans-
genic mice have continuous anagen hair
follicles with hyper melanin production
(Kato et al., 2001, 2004). Moreover, hair
growth of adult transgenic mice was
promoted compared with that of control
C57BL/6 mice (Kato et al., 2001). These
results suggest that a continuous anagen
phase of hair follicles plays an important
role in hair growth.
We also established another RET-
transgenic mouse line (304/B6) (Kato
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et al., 1998a, b, 1999). The process of
benign tumor development and its
malignant transformation in the 304/
B6 line macroscopically resembles that
of the human giant congenital melano-
cytic nevus, which is present at birth
and frequently gives rise to malignant
melanoma. However, we could not
notice a melanocytic nevus in the
dermis when we reported the mouse
line (Kato et al., 1998a, b, 2000). In
fact, very limited numbers of mouse
lines with spontaneously developed
nevi have been reported. Alternatively,
nevi are inducible in animals by treatment
with 7,12-dimethylbenzanthracene and/
or UV light irradiation (Elmets et al.,
2004; Menzies et al., 2004).
In this study, we crossed the original
RET-transgenic mice of line 242 with
hairless HRS/J mice and newly
prepared a hairless RET (HL/RET)-trans-
genic mouse of line 242-hr/hr in the
Animal Center of Nagoya University,
which approved the experiment. As
expected, skin of the HL/RET-transgenic
mouse (Figure 1a bottom, d) was highly
pigmented compared with that of
the control albino non-transgenic hair-
less mouse (Figure 1a top, b) or the
control conventionally pigmented (non-
albino) non-transgenic hairless mouse
(Figure 1c).
Using this new mouse line, we for
the first time investigated RET-asso-
ciated hair growth in mice bearing an
hr/hr genotype. Although no anagen is
usually observed in hair follicles from
adult wild-type hairless mice (Figure 1b
and c), most hair follicles in the HL/
RET-transgenic mice were anagen
(Figure 1d). These results suggest that
the activated RET gene partially comple-
mented the hairless defect. As shown
in Figure 1a (bottom), however, no
hairs were macroscopically observed
in the HL/RET-transgenic mice. Other
factors in addition to anagen may be
necessary for hair development.
Unexpectedly, melanocytic nevi
with slightly enlarged lymph nodes
with hyperpigmentation in the dermis
were microscopically found to develop
up to 10 days after birth in 90% (18/20)
of the HL/RET-transgenic mice (Figure
1d and e), suggesting that the nevi
are of genetic origin rather than
environmental origin. The histopatho-
logical characteristics of the nevi in the
HL/RET-transgenic mice were compati-
ble with those of human congenital
melanocytic nevi, for which an impor-
tant criterion for diagnosis is the pre-
sence of melanocytes (S-100-positive
cells) along epithelial structures of
adnexa and their angiocentric distribu-
tion (white arrows in Figure 1e and f)
(Kerl et al., 2006). On the other hand,
there is histopathologically a slight
increase in the number of melanocytes
in hyperpigmented skin of the HL/RET-
transgenic mice (black arrowheads in
Figure 1d, e, and f) (Kerl et al., 2006).
Benign melanocytic tumors in the
original haired RET-transgenic mice of
line 304/B6 (white arrow in Figure 1g)
are histologically in the subcutaneous
lesion (white arrow in Figure 1h). Based
on these findings and the difference in
macroscopic appearance (Figure 1a
and g), we finally concluded that the
nevi in the dermis in HL/RET-transgenic
mice of line 242-hr/hr are different from
hyperpigmented skin and benign mela-
nocytic tumors, and we finally dia-
gnosed them as congenital melanocytic
nevi.
Recently, hyperpigmented skin has
been reported in steel factor (SLF)-, N-
ras-, and Ha-ras-transgenic mouse lines
(Powell et al., 1995; Kunisada et al.,
1998; Ackermann et al., 2005). Nevi
were found in the Ha-ras-transgenic
mouse line (Powell et al., 1995) but
not in SLF- and N-ras-transgenic mouse
lines (Kunisada et al., 1998; Ackermann
et al., 2005).
The reason why the nevi developed
in the HL/RET-transgenic mice is un-
known. However, the hairless mice
have a significant depression of
T-cell, but not B-cell, immune response
(Johnson et al., 1982). Therefore,
T-cell-mediated immune response may
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Figure 1. Macroscopic and microscopic characteristics of HL/RET-transgenic mice. Macroscopic
(a, g) and microscopic (b–f, h) appearances of control skin (b, c), hyperpigmented skin (d, black
arrowheads in e and f), congenital melanocytic nevus (white arrows in e and f), and benign tumor
(white arrow in g and h) from a representative 12-week-old HL/RET-transgenic mouse of line 242-hr/hr
(bottom mouse of a, d, e, f), a control 12-week-old hairless non-transgenic albino mouse (top mouse of a,
b), a control 12-week-old hairless non-transgenic conventionally pigmented (non-albino) mouse (c), and
an original haired 12-week-old RET-transgenic mouse of line 304/B6 (g, h) are presented. Tissues were
stained with hematoxylin and eosin (b–e, h) or immunohistochemically with anti-S100 antibody (f). There
were basically no differences between an albino non-transgenic hairless mouse and a pigmented hairless
mouse in hair cycle (b, c) and macroscopic appearance (data not shown). The nevus was composed of
S100-positive round or spindle-shaped cells with round nuclei and without a mitotic profile (e, f).
Melanophages were also observed in the nevus (e, f). The benign tumor in the original RET-transgenic
mice of line 304/B6 consisted of S-100-positive cells as reported previously (data not shown) (Iwamoto
et al., 1991; Kato et al., 1998a, b). Immunohistochemistry was performed by a previously reported
method (Kato et al., 2004). Bar¼100 mm (b, c) and 200 mm (d, e, f, h).
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be involved in the development of nevi.
On the other hand, it was reported that
congenital melanocytic nevi have a
significantly higher risk for develop-
ment of a malignant melanoma in
humans (Zaal et al., 2005). No malig-
nant melanomas developed from the
nevi in the HL/RET-transgenic mice of
line 242 (n4200) throughout their life
(41.5 years). However, melanomas
may be inducible in the HL/RET-trans-
genic mice by treatment of the nevi
with 7,12-dimethylbenzanthracene or
injection of cultured melanocytes from
the nevi for immunodeficient mice.
Moreover, the HL/RET-transgenic mice
might be useful for analyzing the
mechanisms of nevus development
and the recently suggested linkage
between nevus development and onset
of some popular diseases. For example,
two study groups reported that children
with atopic dermatitis had few melano-
cytic nevi (Broberg and Augustsson,
2000; Synnerstad et al., 2004). One of
those groups also revealed that there
was a significant negative correlation
between serum IgE and number of nevi
in patients with atopic dermatitis. An-
other group reported that allergic
rhinitis easily developed in individuals
with few nevi (Awaya et al., 2003).
Unfortunately, however, the mechan-
isms underlying these apparently im-
portant observations have not been
clarified because these studies were
performed only in humans. There was
no clear difference between serum IgE
levels in young aged (less than 6-month
old) HL/RET-transgenic mice and
control wild-type mice in our prelimin-
ary examination (Kato et al., unpub-
lished observation). However, it might
be possible to determine the basic
mechanisms underlying the correlation
between nevus development and
occurrence of atopic dermatitis by
crossing the nevi-developing HL/RET-
transgenic mouse with a previously
reported hairless model mouse with
atopic dermatitis (Matsumoto et al.,
2005). On the other hand, allergic
rhinitis is easily inducible by treatment
with ovalbumin (Hellings et al.,
2001). Therefore, the mechanism
underlying the negative correlation
between nevus development and occ-
urrence of allergic rhinitis might be
clarified through comparison of the
sensitivity for ovalbumin-induced aller-
gic rhinitis in HL/RET-transgenic mice
and that in control hairless mice.
In summary, we have newly estab-
lished a hairless mouse line with
hyperpigmented skin and continuous
anagen hair follicles. Using this mouse
model, we demonstrated that a contin-
uous anagen phase of follicles is not a
sufficient condition for hair growth.
More interestingly, we found that mel-
anocytic nevi develop spontaneously in
the transgenic mouse line. This novel
mouse model may open a new window
in research on biology and related
pathogenic events of melanocytic nevi.
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